Physician profile
Simone Nader
NPI 1922075134
$9,605.72
in general payments reported to CMS, 2019-2025
41 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $781 · 2021: $1,576 · 2022: $1,091 · 2023: $1,808 · 2024: $1,538 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,989.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,146.55 | 2019-2025 | |
| Amgen INC. | $960.11 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $850.97 | 2020-2025 | Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $772.62 | 2019-2025 | Lifevest |
| Pfizer INC. | $723.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $632.26 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $589.01 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $569.87 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $407.84 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $363.54 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $340.87 | 2021-2025 | |
| Abbott Laboratories | $276.24 | 2021-2025 | Triclip |
| Novo Nordisk INC | $259.53 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $234.58 | 2019-2021 | |
| Medtronic, INC. | $233.01 | 2021-2024 | Cobalt Dr Mri Surescan, Linq II |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $177.59 | 2022-2025 | Barostim Neo System |
| Siemens Medical Solutions USA, INC. | $124.99 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $105.53 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $96.69 | 2025 | Amvuttra |
| Boston Scientific Corporation | $83.97 | 2020-2025 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $66.37 | 2024 | Arcalyst |
| Shockwave Medical, INC | $60.07 | 2021 | |
| Esperion Therapeutics, INC. | $58.45 | 2023-2024 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $52.08 | 2024-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $44.77 | 2021-2024 | |
| Lexicon Pharmaceuticals, INC. | $40.97 | 2023-2024 | Inpefa |
| Biotronik INC. | $38.68 | 2022 | |
| Impulse Dynamics (USA) INC. | $33.91 | 2022 | |
| Ge Healthcare | $32.06 | 2021 | |
| Philips North America LLC | $30.38 | 2024 | (Ck4) Mcot |
| Atricure, INC. | $26.68 | 2025 | Synergy Ablation System |
| Kiniksa Pharmaceuticals, Ltd. | $25.67 | 2023 | Arcalyst |
| Celgene Corporation | $25.09 | 2025 | Eliquis |
| Altathera Pharmaceuticals LLC | $17.77 | 2024 | Sotalol Hydrochloride |
| Baxter Healthcare | $16.72 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Irhythm Technologies, INC. | $16.04 | 2021 | |
| Scpharmaceuticals INC. | $15.97 | 2025 | |
| Cleerly, INC. | $15.61 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Gilead Sciences, INC. | $15.45 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.14 | 2019 | |
| Medtronic Vascular, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Nader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.